Profound Medical Corp.

NASDAQ:PROF

Medical - Devices

Healthcare
$6.91 +4.11%

+$0.27 today

Market cap
$253.09M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $3.76High $8.95

Volume 0.08M

Average 0.12M

PROF Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Profound Medical Corp.NASDAQ: PROF

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 8.7% from a year ago

Cash & equivalents stood at $50.46M at the end of Q1 FY2026, up 8.7% from a year earlier and down 38.3% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.

Context

  • Cash & equivalents amounted to 68.5% of total assets at the end of Q1 FY2026, down 7.8 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +8.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$50.46M-38.3% QoQ
Last fiscal yearDec 2025
$81.8M+49.0% YoY
Year agoMar 2025
$46.43M+8.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.7%——
1 year+49.0%——
3-year CAGR+20.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
81.8M USD
Year-over-year change
+49.0%
4-year CAGR
+5.1%

Cash & Equivalents vs competitors

How PROF compares with its peers on the latest reported figures

  • PROF's Mar 2026 cash & equivalents of $50.46M is the 5th highest of the 11 companies compared; the peer median is $45.08M.
  • Its year-over-year change of +8.7% is the 7th highest of 11, against a peer median of +19.2%.
  • Cash & equivalents amounts to 68.5% of total assets for PROF, versus a peer median of 24.6%.
PROF Competitors Peer median
Cash & Equivalents for PROF and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AVRAnteris Technologies Global Corp.Mar 2026$283.21M +478.5%+10.6%96.1%
TLSITriSalus Life Sciences, Inc.Mar 2026$56.55M +335.0%+29.5%79.7%
PREPrenetics Global LimitedMar 2026$56.02M +16.8%-39.7%32.0%
CATXPerspective Therapeutics, Inc.Mar 2026$53.97M +21.5%+13.4%13.1%
PROFProfound Medical Corp.Mar 2026$50.46M +8.7%+20.7%68.5%
NNOXNano-X Imaging Ltd.Dec 2025$49.15M +25.1%+8.5%30.3%
OWLTOwlet, Inc.Mar 2026$41.01M +151.4%+46.8%47.3%
MXCTMaxCyte, Inc.Mar 2026$14.56M -37.8%+21.9%7.5%
STIMNeuronetics, Inc.Mar 2026$13.21M -37.7%-21.4%10.5%
LNSRLENSAR, Inc.Mar 2026$12.49M -36.1%-4.0%18.9%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$4.75M -59.3%-16.4%6.8%
Peer median (excluding PROF) $45.08M+19.2%+9.6%24.6%

Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents67.06M46.52M26.21M54.91M81.8M
Short-term Investments00000
Net Receivables1.41M6.34M7.29M7.05M9.86M
Inventory7.4M7.94M6.99M5.8M11.28M
Other Current Assets1.15M0001.27M
Total Current Assets77.02M62.02M41.9M69.07M104.21M
Property, Plant & Equipment (Net)1.9M1.72M1.57M821.01K225K
Goodwill2.69M0000
Intangible Assets1.43M680K490K261K138K
Long-term Investments3.62M000410.89K
Tax Assets00087K0
Other Non-current Assets000087.96M
Total Non-current Assets9.64M2.4M2.06M1.17M88.73M
Total Assets86.66M64.42M43.96M70.23M192.94M
Account Payables3.18M2.03M865K1.32M2.14M
Short-term Debt249.66K523K2.1M1.74M291.73K
Tax Payables0298K000
Deferred Revenue476.35K471K721K419K0
Other Current Liabilities247.66K621K1.42M1.03M5.83M
Total Current Liabilities4.15M4.19M6.37M6.57M8.32M
Long-term Debt06.65M5M2.92M6.16M
Deferred Tax Liabilities0059K086.83M
Deferred Revenue (Non-current)873.82K764K728K49K531.42K
Other Non-current Liabilities0073K71K108.2K
Total Non-current Liabilities2M8.23M6.36M3.25M93.63M
Total Liabilities6.15M12.42M12.73M9.81M101.95M
Common Stock219.28M205.83M222.21M281.55M443.54M
Retained Earnings(160.48M)(189.36M)(217.35M)(245.17M)(394.1M)
Accumulated OCI4.74M16.84M5.57M2.74M6.88M
Other Stockholders Equity00000
Minority Interest00000
Total Equity80.51M52M31.22M60.42M90.99M
Total Debt1.38M8.23M7.87M5.12M6.45M
Net Debt(65.69M)(38.29M)(18.35M)(49.79M)(75.34M)

Profound Medical Corp.

NASDAQ:PROF

Intrinsic Alpha fair value

Locked

Current Price

$6.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.